| Primary |
| Drug Use For Unknown Indication |
34.1% |
| Product Used For Unknown Indication |
14.5% |
| Pneumonia |
9.0% |
| Bacteraemia |
6.8% |
| Hypertension |
6.8% |
| Infection |
3.7% |
| Avian Influenza |
3.1% |
| Tenosynovitis |
2.6% |
| Meningitis |
2.0% |
| Urinary Tract Infection |
2.0% |
| Glaucoma |
1.8% |
| Toxic Epidermal Necrolysis |
1.8% |
| Cough |
1.5% |
| Infection Prophylaxis |
1.5% |
| Pain |
1.5% |
| Prophylaxis |
1.5% |
| Pyrexia |
1.5% |
| Immunosuppressant Drug Therapy |
1.3% |
| Rheumatoid Arthritis |
1.3% |
| Sepsis |
1.3% |
|
| Death |
11.3% |
| Toxic Epidermal Necrolysis |
9.9% |
| Cholelithiasis |
7.8% |
| Renal Failure Acute |
7.8% |
| Vomiting |
7.8% |
| Rash |
5.7% |
| Tachycardia |
5.7% |
| Loss Of Consciousness |
5.0% |
| Pyrexia |
4.3% |
| Acute Respiratory Distress Syndrome |
3.5% |
| Anaphylactic Reaction |
3.5% |
| Pneumonia |
3.5% |
| Renal Impairment |
3.5% |
| Urticaria |
3.5% |
| Anaphylactic Shock |
2.8% |
| Hepatitis |
2.8% |
| International Normalised Ratio Increased |
2.8% |
| Multi-organ Failure |
2.8% |
| Renal Failure |
2.8% |
| Shock |
2.8% |
|
| Secondary |
| Product Used For Unknown Indication |
27.2% |
| Drug Use For Unknown Indication |
17.4% |
| Pneumonia |
8.2% |
| Pyrexia |
4.3% |
| Hypertension |
4.2% |
| Agitation |
3.9% |
| Lung Disorder |
3.6% |
| Bacteraemia |
3.2% |
| Opportunistic Infection Prophylaxis |
3.2% |
| Type 2 Diabetes Mellitus |
3.0% |
| Infection |
2.9% |
| Meningococcal Sepsis |
2.8% |
| Avian Influenza |
2.3% |
| Bronchopneumonia |
2.2% |
| Hiv Infection |
2.1% |
| Prophylaxis |
2.1% |
| Meningitis |
2.0% |
| Bronchitis |
1.8% |
| Cough |
1.8% |
| Urinary Tract Infection |
1.8% |
|
| Acute Respiratory Distress Syndrome |
9.6% |
| Thrombocytopenia |
8.0% |
| Ventricular Extrasystoles |
8.0% |
| Pseudomembranous Colitis |
6.4% |
| Renal Failure Acute |
6.4% |
| Toxic Epidermal Necrolysis |
6.4% |
| Urticaria |
6.4% |
| Drug Level Increased |
5.6% |
| Pyrexia |
5.6% |
| Sepsis |
4.8% |
| Clostridium Difficile Colitis |
4.0% |
| Medication Error |
4.0% |
| Vomiting |
4.0% |
| Accidental Overdose |
3.2% |
| Oral Candidiasis |
3.2% |
| Pneumonia |
3.2% |
| Transaminases Increased |
3.2% |
| Tremor |
3.2% |
| Anaphylactic Reaction |
2.4% |
| Cholestasis |
2.4% |
|
| Concomitant |
| Product Used For Unknown Indication |
28.0% |
| Prophylaxis |
9.6% |
| Drug Use For Unknown Indication |
7.1% |
| Pneumonia |
6.9% |
| Infection Prophylaxis |
6.5% |
| Pneumocystis Jiroveci Pneumonia |
6.3% |
| Hiv Infection |
5.0% |
| Hypertension |
4.4% |
| Pulmonary Tuberculosis |
3.1% |
| Pyrexia |
2.6% |
| Diabetes Mellitus |
2.5% |
| Pain |
2.3% |
| Premedication |
2.2% |
| Prophylaxis Against Graft Versus Host Disease |
2.2% |
| Antifungal Prophylaxis |
2.0% |
| Aplastic Anaemia |
1.9% |
| Bone Marrow Conditioning Regimen |
1.9% |
| Intensive Care |
1.9% |
| Non-small Cell Lung Cancer |
1.9% |
| Cardiac Failure |
1.8% |
|
| Stomatitis |
9.8% |
| Pyrexia |
8.5% |
| Thrombocytopenia |
7.9% |
| White Blood Cell Count Decreased |
7.3% |
| Pneumonia |
6.7% |
| Hepatic Function Abnormal |
6.1% |
| Pulmonary Embolism |
6.1% |
| Weight Increased |
5.5% |
| Sepsis |
4.9% |
| Diarrhoea |
4.3% |
| Rhabdomyolysis |
4.3% |
| Delirium |
3.7% |
| Drug Interaction |
3.7% |
| Myositis |
3.7% |
| Vomiting |
3.7% |
| Drug Ineffective |
3.0% |
| Torsade De Pointes |
3.0% |
| White Blood Cell Count Increased |
3.0% |
| Cardiac Arrest |
2.4% |
| Conjunctivitis |
2.4% |
|
| Interacting |
| Product Used For Unknown Indication |
32.7% |
| Pneumonia |
12.2% |
| Atrial Fibrillation |
8.2% |
| Cardiac Disorder |
6.1% |
| Hypertension |
4.1% |
| Renal Failure Chronic |
4.1% |
| Vitamin Supplementation |
4.1% |
| Endocarditis |
3.1% |
| Hypercholesterolaemia |
3.1% |
| Prophylaxis Against Transplant Rejection |
3.1% |
| Abdominal Symptom |
2.0% |
| Allergic Granulomatous Angiitis |
2.0% |
| Bladder Disorder |
2.0% |
| Depression |
2.0% |
| Diabetes Mellitus |
2.0% |
| Gastritis |
2.0% |
| Metastatic Malignant Melanoma |
2.0% |
| Septic Shock |
2.0% |
| Thyroid Disorder |
2.0% |
| Arrhythmia Prophylaxis |
1.0% |
|
| Drug Level Increased |
30.8% |
| Drug Interaction |
15.4% |
| Rhabdomyolysis |
15.4% |
| Abdominal Wall Haematoma |
7.7% |
| Cholestasis |
7.7% |
| Pyrexia |
7.7% |
| Renal Failure Acute |
7.7% |
| Vertigo |
7.7% |
|
